BRPI0907826A2 - inibidores heterocíclicos de estearoil-coa desaturase - Google Patents

inibidores heterocíclicos de estearoil-coa desaturase Download PDF

Info

Publication number
BRPI0907826A2
BRPI0907826A2 BRPI0907826A BRPI0907826A2 BR PI0907826 A2 BRPI0907826 A2 BR PI0907826A2 BR PI0907826 A BRPI0907826 A BR PI0907826A BR PI0907826 A2 BRPI0907826 A2 BR PI0907826A2
Authority
BR
Brazil
Prior art keywords
heterocyclic
coa desaturase
stearoyl coa
desaturase inhibitors
derivatives
Prior art date
Application number
Other languages
English (en)
Inventor
Hou Duanjie
Fu Jianmin
Fonarev Julia
Dales Natalie
Pokrovskaia Natalia
Jia Qi
Sun Shaoyi
Chowdhury Sultan
Kodumuru Vishnumurthy
Zhang Zaihui
Original Assignee
Novartis Ag
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40740143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0907826(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag
Publication of BRPI0907826A2 publication Critical patent/BRPI0907826A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

inibidores heterocíclicos de estearoil- coa desaturase, composição farmacêutica e usos a presente invenção refere-se a derivados heterocíclicos que modulam a atividade de estearoil-coa desaturase. métodos de usar tais derivados para modular a atividade de estearoil-coa desaturase e composi-ções farmacêuticas compreendendo tais derivados são também abrangidos.
BRPI0907826 2008-02-20 2009-02-18 inibidores heterocíclicos de estearoil-coa desaturase BRPI0907826A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3013708P 2008-02-20 2008-02-20
PCT/EP2009/051926 WO2009103739A1 (en) 2008-02-20 2009-02-18 Heterocyclic inhibitors of stearoyl-coa desaturase

Publications (1)

Publication Number Publication Date
BRPI0907826A2 true BRPI0907826A2 (pt) 2019-12-10

Family

ID=40740143

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907826 BRPI0907826A2 (pt) 2008-02-20 2009-02-18 inibidores heterocíclicos de estearoil-coa desaturase

Country Status (28)

Country Link
US (2) US8049016B2 (pt)
EP (1) EP2245029B1 (pt)
JP (2) JP5507474B2 (pt)
KR (1) KR101584826B1 (pt)
CN (1) CN102007123B (pt)
AR (1) AR070429A1 (pt)
AU (1) AU2009216769A1 (pt)
BR (1) BRPI0907826A2 (pt)
CA (1) CA2715947C (pt)
CL (1) CL2009000381A1 (pt)
CO (1) CO6290655A2 (pt)
CR (1) CR11629A (pt)
CU (1) CU23890B1 (pt)
EA (1) EA022797B1 (pt)
EC (1) ECSP10010411A (pt)
HN (1) HN2010001647A (pt)
IL (1) IL207578A (pt)
JO (1) JO3014B1 (pt)
MA (1) MA32150B1 (pt)
MX (1) MX2010009158A (pt)
MY (1) MY156317A (pt)
NZ (1) NZ587350A (pt)
PE (1) PE20091473A1 (pt)
SV (1) SV2010003650A (pt)
TW (1) TWI457338B (pt)
UA (1) UA105000C2 (pt)
WO (1) WO2009103739A1 (pt)
ZA (1) ZA201005725B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110371A1 (es) 2006-08-15 2011-06-24 Novartis Ag COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
AU2007336238A1 (en) * 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as SCD inhibitors
CA2715947C (en) 2008-02-20 2016-10-25 Novartis Ag Heterocyclic inhibitors of stearoyl-coa desaturase
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
AU2010302577A1 (en) * 2009-10-01 2012-03-15 Novartis Ag Pyrazole derivatives which modulate stearoyl-CoA desaturase
AR091022A1 (es) * 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
CN104334546B (zh) 2012-05-21 2017-05-03 诺华股份有限公司 作为激酶抑制剂的新的环‑取代的n‑吡啶基酰胺
EP3511332A4 (en) * 2016-09-08 2020-03-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NEW 2-ACYLAMINOTHIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR AND USE THEREOF
EP3529245A4 (en) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
MA54829A (fr) 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
CN114222732B (zh) * 2019-10-28 2023-04-04 南京明德新药研发有限公司 一种尿酸促排剂及其合成方法和其在医药上的应用
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
KR20220119653A (ko) * 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH590266A5 (pt) * 1972-10-04 1977-07-29 Ciba Geigy Ag
US4058617A (en) * 1972-10-04 1977-11-15 Ciba-Geigy Corporation Imidazoles and pharmaceutical composition
IL44282A (en) 1974-02-25 1979-01-31 Ciba Geigy Ag 1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them
JPH11193281A (ja) 1997-10-27 1999-07-21 Takeda Chem Ind Ltd アデノシンａ３受容体拮抗剤およびチアゾール化合物
EP1205478A4 (en) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
CA2404384A1 (en) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2002051442A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Concomitant drugs
EP1402900A1 (en) 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
US20090192191A1 (en) 2004-01-09 2009-07-30 Braj Bhushan Lohray Substituted hydroxamic acid derivatives as tnf inhibitors
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP2316458A1 (en) * 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US7767677B2 (en) * 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2029138A1 (en) * 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
DE602007010287D1 (de) * 2006-06-05 2010-12-16 Novartis Ag Organische verbindungen
PE20110371A1 (es) * 2006-08-15 2011-06-24 Novartis Ag COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
MX2009003080A (es) * 2006-09-22 2009-04-02 Novartis Ag Compuestos organicos heterociclicos.
GB0621452D0 (en) * 2006-10-27 2006-12-06 Ucl Business Plc Therapy for liver disease
AU2007336238A1 (en) * 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as SCD inhibitors
JPWO2009101917A1 (ja) * 2008-02-13 2011-06-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 ビシクロアミン誘導体
CA2715947C (en) 2008-02-20 2016-10-25 Novartis Ag Heterocyclic inhibitors of stearoyl-coa desaturase
WO2009156484A2 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2014132025A (ja) 2014-07-17
HK1144808A1 (en) 2011-03-11
AR070429A1 (es) 2010-04-07
EP2245029A1 (en) 2010-11-03
JO3014B1 (ar) 2016-09-05
JP5813162B2 (ja) 2015-11-17
CN102007123A (zh) 2011-04-06
CR11629A (es) 2010-11-16
NZ587350A (en) 2012-07-27
ZA201005725B (en) 2011-04-28
CN102007123B (zh) 2014-04-30
CA2715947A1 (en) 2009-08-27
TW200942534A (en) 2009-10-16
US8049016B2 (en) 2011-11-01
IL207578A0 (en) 2010-12-30
CU23890B1 (es) 2013-04-19
CU20100170A7 (es) 2011-10-31
KR20100117677A (ko) 2010-11-03
TWI457338B (zh) 2014-10-21
US20120014906A1 (en) 2012-01-19
JP2011512384A (ja) 2011-04-21
US8318949B2 (en) 2012-11-27
UA105000C2 (uk) 2014-04-10
US20090264444A1 (en) 2009-10-22
MX2010009158A (es) 2010-09-24
AU2009216769A1 (en) 2009-08-27
MA32150B1 (fr) 2011-03-01
ECSP10010411A (es) 2010-09-30
EA022797B1 (ru) 2016-03-31
CO6290655A2 (es) 2011-06-20
KR101584826B1 (ko) 2016-01-18
CL2009000381A1 (es) 2010-09-10
EP2245029B1 (en) 2015-04-15
MY156317A (en) 2016-02-15
IL207578A (en) 2014-11-30
PE20091473A1 (es) 2009-10-23
CA2715947C (en) 2016-10-25
WO2009103739A1 (en) 2009-08-27
HN2010001647A (es) 2013-11-11
JP5507474B2 (ja) 2014-05-28
SV2010003650A (es) 2011-07-05
EA201001315A1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
CU23914B1 (es) DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL CoA
NO20084334L (no) Farmasoytiske sammensetninger
CU23890B1 (es) Inhibidores heterocíclicos de estearoil-coa-desaturasa
MX2009003080A (es) Compuestos organicos heterociclicos.
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
CR20110240A (es) Inhibidores de cinasa akt y p70 s6
MX2009006728A (es) Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
BR112012007509A2 (pt) derivados pirazóis que modulam estearoil-coa dessaturase
GEP20156241B (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
MX2012004780A (es) Inhibidores de akt.
BRPI0914305B8 (pt) compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos
ATE509931T1 (de) Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür
TN2010000378A1 (en) Heterocyclic inhibitors of stearoyl-coa desaturase
TN2010000598A1 (en) Organic compounds
UA107927C2 (en) Aryl pyridine as inhibitors of aldosterone synthase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A E 11A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2554 DE 17/12/2019.

B350 Update of information on the portal [chapter 15.35 patent gazette]